Use this link to cite:
https://hdl.handle.net/2183/49791 Live Auxotrophic Vaccines Contribute to Protection Against Chronic Lung Infections Caused by Pseudomonas Aeruginosa in C57BL/6 Mice
Loading...
Identifiers
Publication date
Authors
Fuentes-Valverde, Víctor
Correia, Alexandra
García, Patricia
Pérez-Antón, Elena
Amorim, Irina
Rumbo-Feal, Soraya
Cabral, M. P.
Vilanova, Manuel
Moscoso, Miriam
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Fuentes-Valverde V, Correia A, García P, Pérez-Antón E, Amorim I, Rumbo-Feal S, Cabral MP, Vilanova M, Moscoso M, Bou G. Live auxotrophic vaccines contribute to protection against chronic lung infections caused by Pseudomonas aeruginosa in C57BL/6 mice. Front Immunol. 2026 Sep 3;17:1862061.
Type of academic work
Academic degree
Abstract
[Abstract] Pseudomonas aeruginosa causes severe, often multidrug-resistant lung infections, especially in individuals with cystic fibrosis, highlighting vaccination as a promising preventive approach. This study evaluated intranasal and intradermal immunization with a D-glutamate auxotrophic P. aeruginosa strain (PAO1 ΔmurI) and two of its derivatives, one with additional D-alanine auxotrophy and another exhibiting reduced lipopolysaccharide-associated toxicity, in C57BL/6 mice using both acute and chronic lung infection models. Mice received two or three doses at various intervals, and safety was assessed through clinical and weight monitoring. A high-dose, 2-administration intranasal regimen protected against acute infection but induced transient weight loss, while a lower-dose, 3-administration regimen minimized toxicity. Immunized mice exhibited robust IL-17A production and increased IFN-γ responses. Following challenge with mucoid strains, vaccinated mice showed reduced lung bacterial loads, suggesting a partial protection against chronic infection. These findings support the potential of auxotrophic live vaccines to mitigate disease severity in patients with cystic fibrosis.
Description
Editor version
Rights
Attribution 4.0 International







